Investigating the effects of long-term dornase alfa use on lung function using registry data

Area of Science:

• Pulmonology
• Pharmacology
• Biochemistry

Background:

• Dornase alfa (DNase) is a common long-term treatment for cystic fibrosis (CF).
• Previous studies have not thoroughly evaluated the long-term effectiveness of DNase therapy.
• This study investigates sustained lung function benefits of DNase over several years.

Purpose of the Study:

• To assess the long-term effects of DNase on lung function in CF patients.
• To determine if DNase benefits are sustained beyond one year of use.
• To explore if treatment effectiveness varies by baseline lung function or age.

Main Methods:

• Analysis of UK CF Registry data from 4,198 individuals (2007-2015).
• Utilized g-estimation to control for time-dependent confounding.
• Estimated effects of DNase on percent predicted FEV1 (ppFEV1) and subgroup differences.

Main Results:

• No significant overall effect of one-year DNase use on lung function (change in ppFEV1: -0.1%, p=0.51).
• DNase demonstrated significant benefit in patients with lower baseline lung function (ppFEV1 < 70%).
• These benefits in lower lung function group were sustained up to five years; no age-dependent effect observed.

Conclusions:

• DNase therapy provides a significant, sustained improvement in lung function for CF patients with reduced baseline lung function (ppFEV1 < 70%).
• The treatment induces a step-change improvement but does not alter the rate of lung function decline.
• No lung function benefit was observed in patients initiating DNase with ppFEV1 > 70%.